Filtered By:
Source: Diabetes, Obesity and Metabolism
Condition: Diabetes Mellitus

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow ‐Up: A Subgroup Analysis of High‐Risk ACCORDION Trial Participants
Abstract Although guidelines recommend strict blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, the long‐term effects of this approach are unknown. We investigated the effect of intensive BP control on clinical outcomes in patients with T2DM over 9 years of follow‐up. We included ACCORD BP participants in the standard glucose control arm who had established cardiovascular disease, chronic kidney disease, age ≥75 years or 10‐year coronary heart risk ≥15%. Participants were randomized to either intensive (systolic BP <120 mm Hg) or standard (systolic B...
Source: Diabetes, Obesity and Metabolism - February 9, 2018 Category: Endocrinology Authors: Leo F. Buckley, Dave L. Dixon, George F. Wohlford, Dayanjan S. Wijesinghe, William L. Baker, Benjamin W. Van Tassell Tags: BRIEF REPORT Source Type: research

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

Association of glucagon ‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Conclusions GLP‐1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - July 5, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users
ConclusionsThis study provides evidence of increased CVD risk associated with hypoglycaemia, especially serious hypoglycaemia events. While associations were attenuated with non‐serious hypoglycaemia, the results were suggestive of a potential increased risk.
Source: Diabetes, Obesity and Metabolism - May 1, 2017 Category: Endocrinology Authors: Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty, David D. Dore Tags: ORIGINAL ARTICLE Source Type: research

Association of Glucagon ‐like Peptide‐1 Receptor Agonist (GLP‐1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System
ConclusionsGLP‐1 RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - April 13, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

Association between diabetes mellitus and incidence and case ‐fatality after stroke due to intracerebral haemorrhage: a retrospective population‐based cohort study
Abstract We investigated the associations between types of diabetes and ICH incidence and case‐fatality after ICH, in a retrospective cohort study of people aged 40–89 years in Scotland 2004–2013 using linkage of population‐based records of diagnosed diabetes, hospital discharges and deaths. We calculated ICH incidence and 30‐day case‐fatality after hospital admission for ICH and their relative risks (RR) and 95% confidence intervals (95%CI) for people with type 1 or type 2 diabetes compared to people without diabetes adjusting for age, sex and socio‐economic status (SES). There were 77, 1275 and 9778 inciden...
Source: Diabetes, Obesity and Metabolism - February 28, 2017 Category: Endocrinology Authors: Marion Boulanger, Rustam Al ‐Shahi Salman, Jan Kerssens, Sarah H. Wild, Tags: BRIEF REPORT Source Type: research

Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research

Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
ConclusionsThis large meta‐analysis indicates that vildagliptin is not associated with an increased risk of adjudicated MACEs relative to comparators. Moreover, this analysis did not find a significant increased risk of HF in vildagliptin‐treated patients.
Source: Diabetes, Obesity and Metabolism - September 10, 2015 Category: Endocrinology Authors: G. McInnes, M. Evans, S. Del Prato, M. Stumvoll, A. Schweizer, V. Lukashevich, Q. Shao, W. Kothny Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17000 patients
ConclusionsThis large meta‐analysis indicates that vildagliptin is not associated with an increased risk for adjudicated MACE relative to comparators. Moreover, this analysis did not find a significant increased risk of HF in vildagliptin‐treated patients.
Source: Diabetes, Obesity and Metabolism - August 1, 2015 Category: Endocrinology Authors: Gordon McInnes, Marc Evans, Stefano Del Prato, Michael Stumvoll, Anja Schweizer, Valentina Lukashevich, Qing Shao, Wolfgang Kothny Tags: ORIGINAL ARTICLE Source Type: research

Patient Empowerment Programme in primary care reduced all‐cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population‐based propensity‐matched cohort study
ConclusionsEnrolment in the PEP was associated with lower all‐cause mortality and a lower number of first CVD events among patients with T2DM. The CVD benefit of PEP might be attributable to improving metabolic control through empowerment of self‐care and the enhancement of quality of diabetes care in primary care.
Source: Diabetes, Obesity and Metabolism - October 20, 2014 Category: Endocrinology Authors: C. K. H. Wong, W. C. W. Wong, Y. F. Wan, A. K. C. Chan, K. L. Chung, F. W. K. Chan, C. L. K. Lam Tags: ORIGINAL ARTICLE Source Type: research

Patient Empowerment Programme (PEP) in Primary Care Reduced All‐cause Mortality and Cardiovascular Diseases in Patients with Type 2 Diabetes Mellitus: A Population‐based Propensity Matched Cohort Study
ConclusionsEnrolment in PEP was associated with reduced all‐cause mortality and first CVD events among T2DM patients. The CVD benefit of PEP might be attributable to improving metabolic control through empowerment of self‐care and enhancement of quality of diabetes care in primary care.
Source: Diabetes, Obesity and Metabolism - September 23, 2014 Category: Endocrinology Authors: Carlos K.H. Wong, William C.W. Wong, Y.F. Wan, Anca K.C. Chan, K.L. Chung, Frank W.K. Chan, Cindy L.K. Lam Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower cardiovascular risk in type‐2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - May 14, 2014 Category: Endocrinology Authors: Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp‐Pedersen, Gunnar Gislason, Lars Køber Tags: ORIGINAL PAPER Source Type: research